Kirkland & Ellis advised ARYA Sciences Acquisition Corp IV (Nasdaq: ARYD) (“ARYA IV”), a special purpose acquisition company sponsored by Perceptive Advisors, on its acquisition of the gene therapy business of Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company. In connection with the closing of the transaction, ARYA IV will be named Caritas Therapeutics, Inc. and will redomicile as a Delaware corporation and its common stock is expected to be listed on Nasdaq under the ticker symbol “SPES.”  In connection with the acquisition, a group of investors has committed to invest in Caritas through a common stock private investment in public equity (PIPE) of approximately $200 million at $10 per share. Completion of the transaction is expected in the fourth quarter of 2021 or early 2022.

Read the ARYA IV press release 

The Kirkland team was led by corporate partners Ryan Brissette and Jonathan Davis and associate Peter Fritz, capital markets partner Peter Seligson, tax partners Sara Zablotney and Mark Schwed, and technology & IP transactions partners Adam Petravicius and Shellie Freedman.